1Corrales JJ;Lopez A;Ciudad J.Methimazole therapy in Graves′ disease influences the abnormal expression of CD69 (early activation antigen) on T cells[J],1997(3).
3Corrales JJ;Orfao A;Lopez A.Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity[J],1997.
4Megumi F;Ken O;Kaori S.Usefulness of surface phenotype study of intrathyroidal lymphocyte obtained by fine needle aspirtion cytology in autoimmune thyroid disease and malignant lymphoma of the thyroid[J],1998.
二级参考文献10
1Stevens LA,Mottet C,Mason D,et al.Human CD4+ CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro[].European Journal of Immunology.2001
2Suri-Pyer E,Amar AZ,Thornton AM,et al.CD4+ CD25+ immunoregulatory T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells[].J Immunol.1998
3Hall BM.Mechanisms of induction of tolerance to allografts[].Critical Reviews in Immunology.2000
4Shevach EM,McHugh PS,Piccirillo CA,et al.Control of T cell activation by CD4+ CD25+ suppressor T cells[].Immunological Reviews.2001
5Asano M,Toda M,Sakaguchi N,et al.Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation[].The Journal of Experimental Medicine.1996
6Zhang J,Medaer R,Stinissen P,et al.MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination[].Science.1993
7Bensinger SJ,Banderia A,Jordan MS,et al.Major histocompatibility complex class Ⅱ-positive cortical epithelium mediates the selection of CD4+CD25+ immunoregulatory T cells[].The Journal of Experimental Medicine.2001
8Jordan MS,Boesteanu A,Reed AJ,et al.Thymic selection of CD4+ CD25+ regulatory T cells induced by an agonist self-peptide[].Nature Immunology.2001
9Roncarolo MG,Levings M.The role of different subsets of T regulatory cells controlling autoimmunity[].Current Opinion in Immunology.2000
10Itoh M,Takahashi T,Sakaguchi N,et al.Thymus and autoimmunity:production of CD25+ CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance[].J Immunol.1999
2Al-Humaidi MA. Serum cytokines levels in Graves' disease. Saudi Med J, 2000,21:639-644.
3Smallridge RC, Tsokos GC, Barman KD, et al. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. Clin Diagn Lab Immunol, 1997,4:583-586.
4Ugur-Altun B, Altun A, Arikan E, et al. Relationships existing between the serum cytokines levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocr Res, 2003,29:389-398.
5Komorowski J, Jankiewicz J, Robak J, et al. Cytokines serum levels as the markers of thyroid activation in Graves' disease. ImmunoI Lett, 1998,60 : 143-148.
6Siddiqi A, Monson JP, Wood DF, et al. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab, 1999,84:435-439.
7Senturk T, Kozaci LD, Kok F, et al. Proinflammatory eytokine levels in hyperthyroidism. Clin Invest Med, 2003,26:58-63.
8Mariotti S, Caturegli P, Barbesino G, et al. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases[J]. Clin Endocrinol (Oxf), 1992, 37(5):415-422.
9Jiskra J, Antosova M, Limanova Z, et al. The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases[J]. Clin Exp Immunol, 2009, 156(2):211-216.
10Ugnr-Altun B, Altun A, ArJkan E, etal. Relationships existing between the serum cytokines levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism[J]. Endocr Res, 2003, 29(4):389-398,.
